The Risk Stratification of Papillary Thyroid Cancer With AUS/FLUS by FNA
The Risk Stratification of Papillary Thyroid Cancer With AUS/FLUS by FNA
Purpose: To investigate the clinical characteristics of papillary thyroid cancer (PTC) with
 Bethesda category III (AUS/FLUS) by fine needle aspiration (FNA) and to assisted the
 precision treatment.

 Methods:A total of 290 patients who underwent thyroidectomies or thyroid lobectomies from
 August 2015 to September 2020, following a diagnosis of Bethesda category III (AUS/FLUS) from
 preoperative thyroid FNA were investigated.

 Groups: In order to investigate the clinopathologic characteristics, the patients, were
 grouped according to Cytology,Gender, Tumor size.
Purpose: To investigate the clinical characteristics of papillary thyroid cancer (PTC) with
 Bethesda category III (AUS/FLUS) by fine needle aspiration (FNA) and to assisted the
 precision treatment.

 Methods:A total of 1739 cases diagnosed with Bethesda category III (AUS/FLUS) by FNA from
 August 2015 to September 2020 were reviewed, and 523 patients received thyroidectomy or
 lobectomy. 290 patients were diagnosed with PTC and investigated retrospectively.

 Groups: In order to investigate the clinopathologic characteristics, the patients, were
 grouped according to Cytology,Gender, Tumor size.as follows:AUS and FLUS&AUS/FLUS;male and
 female; tumor size≤1cm and>1cm.
Inclusion Criteria:

 Clinical cytology diagnosis of Bethesda category III (AUS/FLUS) pathological confirmation
 of thyroid malignancy after surgery.

 Exclusion Criteria:

 1. pathological confirmation of other thyroid carcinomas, including follicular carcinoma
 ,medullary carcinoma ,undifferentiated Spindle cell carcinoma and lymphoma were
 excluded

 2. female who were pregnant were excluded

 3. patients with mental disorders were excluded

 4. patients without the complete clinical data were excluded